产品信息
参考资料(来源文献)
| 背景描述 | established from the pleural effusion of a 62-year-old woman with ductal breast cancer (grade 3 invasive, T2N1M0) after postoperative radiation in 2003; cell line was described in the literature to carry an amplified HER-2 oncogene and to be insensitive to HER-2-inhibiting drugs, e.g. trastuzumab (Herceptin); listed in the CCLE (ref 18232) |
| 年龄（性别） | 女性；62岁 |
| 细胞类型 | 肿瘤细胞 |
| 肿瘤类型 | 乳腺导管癌 |
| 生物安全等级 | BSL-1 |
| 倍增时间 | ~30-40 hours (DSMZ=ACC-589); 35.39 hours (GrayJW panel) |
| 保藏机构 | AddexBio; C0006005/50 DSMZ; ACC-589 |
FAQs
Q：{{item.question}}
A：
暂无数据
